AbbVie (ABBV) Free Cash Flow (2012 - 2026)
AbbVie (ABBV) reported Free Cash Flow of $3.6 billion for Q1 2026, up 154.57% year-over-year from $1.4 billion in Q1 2025, and down 27.1% quarter-over-quarter from $4.9 billion in Q4 2025.
AbbVie (ABBV) Free Cash Flow (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has 15 years of Free Cash Flow data on file, last reported at $3.6 billion in Q1 2026.
- Free Cash Flow for Q1 2026 came in at $3.6 billion, up 154.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $20.0 billion (up 29.87% YoY), and the FY2025 annual result was $17.8 billion, changed 0.09% from the prior year.
- Free Cash Flow eased to $3.6 billion in Q1 2026 per ABBV's latest filing, from $4.9 billion in the prior quarter.
- Over five years, Free Cash Flow peaked at $7.4 billion in Q3 2022 and troughed at $1.4 billion in Q1 2025.
- A 5-year average of $5.0 billion and a median of $4.9 billion in 2025 frame the typical range for Free Cash Flow.
- The sharpest annual moves came in 2024 and 2026: Free Cash Flow slumped 66.94% in 2024, then soared 154.57% in 2026.
- A 5-year view of Free Cash Flow shows it stood at $7.2 billion in 2022, then plunged by 36.96% to $4.5 billion in 2023, then soared by 48.57% to $6.8 billion in 2024, then slipped by 27.65% to $4.9 billion in 2025, then slipped by 27.1% to $3.6 billion in 2026.
- Business Quant data shows ABBV's Free Cash Flow at $3.6 billion in Q1 2026, $4.9 billion in Q4 2025, and $6.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 2.12 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 3.01 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 1.47 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 3.56 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 2.93 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 1.48 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 2.43 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 2.18 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 757.00 Mn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | 346.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.56 Bn |
| Mar 31, 2026 | 3.56 Bn |
| Dec 31, 2025 | 4.89 Bn |
| Dec 31, 2025 | 4.89 Bn |
| Sep 30, 2025 | 6.64 Bn |
| Sep 30, 2025 | 6.64 Bn |
| Jun 30, 2025 | 4.88 Bn |
| Jun 30, 2025 | 4.88 Bn |
| Mar 31, 2025 | 1.40 Bn |
| Mar 31, 2025 | 1.40 Bn |
| Dec 31, 2024 | 6.76 Bn |
| Dec 31, 2024 | 6.76 Bn |
| Sep 30, 2024 | 5.20 Bn |
| Sep 30, 2024 | 5.20 Bn |
| Jun 30, 2024 | 2.03 Bn |
| Jun 30, 2024 | 2.03 Bn |
| Mar 31, 2024 | 3.85 Bn |
| Mar 31, 2024 | 3.85 Bn |
| Dec 31, 2023 | 4.55 Bn |
| Dec 31, 2023 | 4.55 Bn |